Over time, some patients develop resistance to crizotinib, rendering the drug less effective. Resistance mechanisms include secondary mutations in the ALK gene, activation of alternative signaling pathways, and histological transformations. Research is ongoing to develop next-generation ALK inhibitors that can overcome these resistance mechanisms and provide effective treatment options for patients.
